Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.

Thrombosis and haemostasis - 1 Dec 2019

Muczynski Vincent, Verhenne Sebastien, Casari Caterina, Chérel Ghislaine, Panicot-Dubois Laurence, Gueguen Paul, Trossaert Marc, Dubois Christophe, Lenting Peter J, Denis Cécile V, Christophe Olivier D

Abstract excerpt

Engineered recombinant factor X (FX) variants represent a promising strategy to bypass the tenase complex and restore hemostasis in hemophilia patients. Previously, a thrombin-activatable FX variant with fibrinopeptide-A replacing the activation peptide (FX-delAP/FpA) has been described in this regard. Here we show that FX-delAP/FpA is characterized by a sixfold shorter circulatory half-life compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Factor X

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia A

Share to Hemostasis

Share to Hepatocytes

Share to Microcirculation

Share to Protein Domains

Share to Thrombin

Source

Identifiers

PMID: 31639831
DOI: 10.1055/s-0039-1697662

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.PMID 31639831Read ↗

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.Semantic proximity Read ↗

Activated Factor X delivered by Adeno-Associated virus significantly inhibited bleeding and alleviated hemophilia A/B arthropathy in hemophilia miceSemantic proximity Read ↗

Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.Semantic proximity Read ↗

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.Semantic proximity Read ↗

Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: hemostatic abnormalities in mutant mice and characterization of the coagulation deficit.Semantic proximity Read ↗

The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.Semantic proximity Read ↗

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.Semantic proximity Read ↗

Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.Semantic proximity Read ↗

Protein-Engineered Coagulation Factors for Hemophilia Gene TherapySemantic proximity Read ↗

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice.Semantic proximity Read ↗

Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male miceSemantic proximity Read ↗

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.